CLINICAL TRIALS AND OBSERVATIONS Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
نویسندگان
چکیده
1Washington University, St Louis, MO; 2Abramson Cancer Center of the University of Pennsylvania, Philadelphia; 3City of Hope Comprehensive Cancer Center, Duarte, CA; 4Mayo Clinic, Rochester, MN; 5Loyola University, Chicago, IL; 6Emory University, Atlanta, GA; 7Oregon Health & Science University, Portland; 8M. D. Anderson Cancer Center, Houston, TX; 9Universitätsklinikum Heidelberg, Heidelberg, Germany; 10Duke University Medical Center; Durham, NC; 11Yale University School of Medicine; New Haven, CT; and 12Genzyme Corporation (formerly AnorMED Inc), Cambridge, MA
منابع مشابه
G-CSF for stem cell therapy in acute myocardial infarction: friend or foe?
Stem cell-based therapy has emerged as a potential therapeutic option for patients with acute myocardial infarction. The ability of granulocyte colony-stimulating factor (G-CSF) to mobilize endogenous stem cells as well as to protect cardiomyocytes at risk via paracrine effects has attracted considerable attention. In the past decade, a number of clinical trials were carried out to study the ef...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma
Autologous stem cell transplantation (ASCT) improves survival in patients with previously untreated multiple myeloma (MM) and relapsed, chemotherapy-sensitive, aggressive non-Hodgkin lymphoma (NHL). Lower relapse rates seen in allogeneic stem cell transplantation have been related to early absolute lymphocyte count (ALC) recovery as a manifestation of early graft-verus-tumor effect. In ASCT, th...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
The aim of the present study was to compare thalidomide-dexamethasone (Thal-Dex) and vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous peripheral blood stem-cell (PBSC) transplantation for multiple myeloma (MM). For this purpose, we performed a retrospective matched case-control analysis of 200 patients who entered 2 consecutive studies from 1996 to 200...
متن کاملCLINICAL TRIALS AND OBSERVATIONS High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study
This prospective study evaluated the risk of arterial thrombosis in 195 consecutive patients aged 18 to 65 years with newly diagnosed multiple myeloma (MM). All patients were treated with 3 cycles of VAD (vincristine, doxorubicin, and dexamethasone) or TAD (thalidomide-AD) or PAD (bortezomib-AD) in national trials, followed by high-dose melphalan and autologous stem cell transplantation. For a ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
The Intergroupe Francophone du Myélome (IFM) initiated 2 trials in 1999 to study patients with high-risk ( 2-microglobulin level greater than 3 mg/L and chromosome 13 deletion at diagnosis) de novo multiple myeloma. In both protocols, the induction regimen consisted of vincristine, doxorubicin, and dexamethasone (VAD) followed by first autologous stem cell transplantation (ASCT) prepared by mel...
متن کامل